CDH2 and prostate cancer: CNTN1 increases tumor cell invasion, migration, and metastasis by promoting EMT via activation of the PI3K/AKT pathway, downregulation of E-cadherin, and upregulation of N-cadherin and vimentin in lung and prostate cancers (14–16, 23, 26).